{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:32:24Z","timestamp":1746595944662,"version":"3.40.3"},"reference-count":48,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Since the mid-20th century, contrast agents have been widely used in radiology due to their ability to provide high-definition radiographic images and greater precision in diagnostic exams. Different types of contrast agents are used in image diagnosis, namely radiological media. Despite being considered safe, there are still uncertainties about their safety profile, interactions, and incidence of adverse drug reactions in real-world settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To characterise the pattern of adverse events, during 7 years, in a radiology unit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We performed a retrospective observational and descriptive study at an Image Center in Portugal between August 2012 and October 2019. A total of 77,449 computed tomography (CT) were registered, and from those 15,640 cases of iopromide were used as a contrast agent. The authors have accessed, under the authorization, the data of adverse events and procedures after the event.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>\n              Most of the hypersensitivity events were immediate or with a short time of onset, with the majority of cases developing events with skin involvement and mild degree, where the most common events were papules (\n              <jats:italic>n<\/jats:italic>\n              =\u00a060), pruritus (\n              <jats:italic>n<\/jats:italic>\n              =\u00a042), erythema (\n              <jats:italic>n<\/jats:italic>\n              =\u00a027) and urticaria (\n              <jats:italic>n<\/jats:italic>\n              =\u00a014). Severe events, including hypersensitivity, were mainly represented by vomiting (\n              <jats:italic>n<\/jats:italic>\n              =\u00a011), stridor (\n              <jats:italic>n<\/jats:italic>\n              =\u00a08), breathing difficulties (\n              <jats:italic>n<\/jats:italic>\n              =\u00a07) and syncope (\n              <jats:italic>n<\/jats:italic>\n              =\u00a03). Abdominal-pelvic CT exam presented a higher frequency of adverse events.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Despite all the current information about iopromide usage, the utilization of this agent is not abstent of risks and its safety profile not fully established. Most frequent symptoms were local, as skin adverse events, including papules, pruritus and erythema. Common medications used to treat or control adverse events were frequently hydrocortisone, clemastine and methylprednisolone.<\/jats:p>\n          <\/jats:sec>","DOI":"10.3233\/jrs-230021","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T14:46:45Z","timestamp":1696603605000},"page":"117-129","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Iopromide safety assessment in a radiology department: A seven-year retrospective characterization of adverse events"],"prefix":"10.1177","volume":"35","author":[{"given":"Jo\u00e3o","family":"Joaquim","sequence":"first","affiliation":[{"name":"Polytechnic Institute of Coimbra,  Coimbra Health School,  Coimbra, Portugal"},{"name":"Department of Pharmaceutical Sciences,  Pharmacy Faculty, University of Salamanca (USAL),  Salamanca, Spain"}]},{"given":"Cristiano","family":"Matos","sequence":"additional","affiliation":[{"name":"Polytechnic Institute of Coimbra,  Coimbra Health School,  Coimbra, Portugal"}]},{"given":"Ramona","family":"Mateos-Campos","sequence":"additional","affiliation":[{"name":"Area of Preventive Medicine and Public Health,  Department of Biomedical and Diagnostic Sciences, University of Salamanca,  Salamanca, Spain"}]}],"member":"179","published-online":{"date-parts":[[2024,5]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-39842009000500010"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00129804-200409000-00004"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0058"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000000611"},{"key":"e_1_3_6_6_2","unstructured":"BrockowK ChristiansenC KannyG Cl\u00e9mentO BarbaudA BircherA Management of hypersensitivity reactions to iodinated contrast media. Wiley Online Library 2005."},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.107.047621"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0284185113504753"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1258\/ar.2011.110359"},{"issue":"1","key":"e_1_3_6_10_2","first-page":"41","article-title":"Protocolo cl\u00ednico de abordagem das rea\u00e7\u00f5es agudas de hipersensibilidade a meios de contraste em Imagiologia","volume":"27","author":"Lopes C","year":"2019","unstructured":"LopesC TavaresC RollaI GomesE. Protocolo cl\u00ednico de abordagem das rea\u00e7\u00f5es agudas de hipersensibilidade a meios de contraste em Imagiologia. Rev Port Imunoalergologia. 2019;27(1):41\u201354.","journal-title":"Rev Port Imunoalergologia"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0b013e3181d4a036"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004424-199405001-00015"},{"issue":"12","key":"e_1_3_6_13_2","first-page":"e3170","article-title":"The incidence, classification, and management of acute adverse reactions to the low-osmolar iodinated contrast media isovue and ultravist in contrast-enhanced computed tomography scanning","volume":"95","author":"Zhang B","year":"2016","unstructured":"ZhangB DongY LiangL LianZ LiuJ LuoX The incidence, classification, and management of acute adverse reactions to the low-osmolar iodinated contrast media isovue and ultravist in contrast-enhanced computed tomography scanning. Med (United States). 2016;95(12):e3170.","journal-title":"Med (United States)"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.5812\/iranjradiol.7696"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2005.00326.x"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1148\/rg.24si045519"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01832.x"},{"issue":"3","key":"e_1_3_6_18_2","first-page":"183","article-title":"Skin test-positive immediate hypersensitivity reaction to iodinated contrast media: The role of controlled challenge testing","volume":"23","author":"Prieto-Garc\u00eda A","year":"2013","unstructured":"Prieto-Garc\u00edaA Tom\u00e1sM PinedaR TorneroP HerreroT FuentesV Skin test-positive immediate hypersensitivity reaction to iodinated contrast media: The role of controlled challenge testing. J Investig Allergol Clin Immunol. 2013;23(3):183\u20139.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_3_6_19_2","unstructured":"INFARMEDIP . Resumo das Caracteristicas do Medicamento - Ultravist (R) [Internet]. 2018. Available from: https:\/\/www.bayer.com\/sites\/default\/files\/2020-11\/Ultravist.pdf."},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2018.39.4160"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.17.18655"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12803"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.06.1328"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/02841850802282811"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-015-0688-9"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.02.035"},{"key":"e_1_3_6_27_2","unstructured":"Bayer Inc. Product monograph: Including patient medication information: ULTRAVIST\u00aeIopromide Injection [Internet]. 2920 Matheson Boulevard East Mississauga Ontario Canada L4W 5R6; 2022. Available from: http:\/\/www.bayer.ca."},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijpp.12078"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00999-0"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01222-y"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620953935"},{"key":"e_1_3_6_33_2","first-page":"1","article-title":"All-round approaches to increase adverse drug reaction reports: A scoping review","author":"Joaquim J","year":"2023","unstructured":"JoaquimJ MatosC GuerraD Mateos-CamposR. All-round approaches to increase adverse drug reaction reports: A scoping review. Drugs & Ther Perspect. 2023;1\u201313.","journal-title":"Drugs & Ther Perspect"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2007.01313.x"},{"issue":"6","key":"e_1_3_6_35_2","first-page":"442","article-title":"2 reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice","volume":"21","author":"Mertes PM","year":"2011","unstructured":"MertesPM MalinowskyJM JouffroyL AbererW TerreehorstI BrockowK 2 reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011;21(6):442.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91953-5"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2019.06.002"},{"issue":"1","key":"e_1_3_6_38_2","first-page":"9","article-title":"Rea\u00e7\u00f5es adversas a meios de contraste iodados","volume":"27","author":"Marcelino J","year":"2019","unstructured":"MarcelinoJ CarvalhoS DuarteFC CostaAC BarbosaMP. Rea\u00e7\u00f5es adversas a meios de contraste iodados. Rev Port Imunoalergologia. 2019;27(1):9\u201320.","journal-title":"Rev Port Imunoalergologia"},{"key":"e_1_3_6_39_2","first-page":"90","article-title":"Rea\u00e7\u00f5es de hipersensibilidade a meios de contraste em idade pedi\u00e1trica","volume":"25","author":"Almiro MM","year":"2016","unstructured":"AlmiroMM MaiaC BrancoL PedrosaC RomarizJ Pra\u00e7aF Rea\u00e7\u00f5es de hipersensibilidade a meios de contraste em idade pedi\u00e1trica. Rev Nascer e Crescer. 2016;25:90\u20138.","journal-title":"Rev Nascer e Crescer"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1159\/000320760"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.05.283"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018172524"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.2478\/cipms-2023-0018"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1996.tb00040.x"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629040-00004"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932010-00002"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/jonm.12337"},{"key":"e_1_3_6_48_2","first-page":"1","article-title":"Attitudes and knowledge of community pharmacy professionals regarding the spontaneous reporting of adverse drug reactions: A preliminary study in Coimbra, Portugal","author":"Matos C","year":"2016","unstructured":"MatosC JoaquimJ PiresT. Attitudes and knowledge of community pharmacy professionals regarding the spontaneous reporting of adverse drug reactions: A preliminary study in Coimbra, Portugal. Drugs Ther Perspect. 2016;1\u20137.","journal-title":"Drugs Ther Perspect"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-017-0380-3"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JRS-230021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JRS-230021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JRS-230021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:19:35Z","timestamp":1742959175000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JRS-230021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.3233\/JRS-230021"],"URL":"https:\/\/doi.org\/10.3233\/jrs-230021","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"type":"print","value":"0924-6479"},{"type":"electronic","value":"1878-6847"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}